Litcius/Paper detail

Recombinant Fasciola hepatica Fatty Acid Binding Protein as a Novel Anti-Inflammatory Biotherapeutic Drug in an Acute Gram-Negative Nonhuman Primate Sepsis Model

Jose J. Rosado-Franco, Albersy Armina-Rodriguez, Nicole Marzan-Rivera, Armando G. Burgos, Natalie Spiliopoulos, Stephanie M. Dorta-Estremera, Loyda B. Mendez, A. M. Espino

2021Microbiology Spectrum10 citationsDOIOpen Access PDF

Abstract

Sepsis caused by Gram-negative bacteria affects 1.7 million adults annually in the United States and is one of the most important causes of death at intensive care units. Although the effective use of antibiotics has resulted in improved prognosis of sepsis, the pathological and deathly effects have been attributed to the persistent inflammatory cascade. There is a present need to develop anti-inflammatory agents that can suppress or neutralize the inflammatory responses and prevent the lethal consequences of sepsis. We demonstrated here that a small molecule of 14.5 kDa can suppress the bacteremia, endotoxemia, and many other inflammatory markers in an acute Gram-negative sepsis rhesus macaque model. These results reinforce the notion that Fh15 constitutes an excellent candidate for drug development against sepsis.

Topics & Concepts

Proinflammatory cytokineSepsisLipopolysaccharideBiologyImmunologyCytokineFasciola hepaticaInflammationCytokine stormMicrobiologyAcute-phase proteinImmune systemSeptic shockPharmacologyRecombinant DNAInnate immune systemLipid AReceptorInterleukin 10Tumor necrosis factor alphaFatty acid-binding proteinBacteriaTLR4AntibioticsAntimicrobial peptidesHelminth infection and controlCoccidia and coccidiosis researchVeterinary Pharmacology and Anesthesia